Important date

ERG Appoints Daniel Gruener, MD as Chief Medical Officer

Effective, November 1, 2017, Daniel Gruener, MD assumed the position of Chief Medical Officer (CMO) of Evolution Research Group, LLC (ERG).  Dr. Gruener is a highly-respected research investigator, psychiatrist, and industry leader in pain and addiction.  He joined ERG in 2015 as Medical Director of St. Louis Clinical Trials and Vice President of Clinical and Scientific Affairs.  He will continue conducting trials as a Principal Investigator at SLCT, but now will lead the large medical team across all sites at ERG.

When asked about his new role within ERG’s senior management structure, Dr. Gruener responded, “I am excited and honored to assume the CMO position at Evolution Research Group.  During my three years with the company, I have seen it continue to evolve and expand into the largest group of wholly-owned, privately-held, quality-driven neuroscience research units in the US.”  Working more closely with the other physicians and clinicians at ERG has been a goal of Gruener’s as he added, “I look forward to helping the leadership and clinical teams continue to accelerate quality driven strategies that result in innovative new treatments for patients and expand our strong relationships within the industry.”

Dr. Bernadette D’Souza, ERG’s Chief Scientific Officer, is extremely enthusiastic about collaborating even more closely with Dr. Gruener, stating, “Dr. Gruener is a highly respected physician and is sought out by sponsors for his expertise in pain and other CNS areas. I am very excited for him to start in his role as the CMO at ERG and look forward to working closely with him.”  As D’Souza and Gruener have collaborated on multiple studies, and participated in advisory boards together, D’Souza added, “Dan’s clinical acumen, leadership and strong relationships in the industry make him an invaluable addition to the ERG senior management team.”

ERG owns and operates nine specialty inpatient and outpatient, early and late phase research units and manages a network of 11 affiliate research sites.  The company established itself as a leader in psychiatry, addiction, sleep and neurology and has continued to add capabilities, such as postsurgical pain trials at three units, deepening its CNS expertise.  This was an important factor in selecting Gruener as its CMO, explained Lori Wright, ERG’s Chief Executive Officer, “I have known Dan for more than ten years and he is one of the most well-rounded clinicians at ERG.  His experience in pain management, psychiatry, addictions, abuse liability/potential, hepatitis, diabetes, and others, made him the natural choice for CMO when Dr. Mofsen vacated the role to pursue other opportunities.”